Omniab, Inc. splits its revenue into 4 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Services at $2.8 million, 71% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
40
|
4
|
13
|
14
|
8
|
2
|
4
|
4
|
11
|
| Services |
10
+27.7%
share 24.0%
|
3
+138.6%
share 71.0%
|
2
+27.7%
share 18.4%
|
2
+10.7%
share 14.6%
|
2
-11.7%
share 26.7%
|
1
share 53.1%
|
2
share 49.7%
|
2
share 45.8%
|
3
share 23.4%
|
| X Ploration Revenue |
2
share 4.8%
|
1
+850.0%
share 17.6%
|
1
+91.0%
share 8.7%
|
0
+28.6%
share 0.4%
|
—
|
0
share 3.3%
|
1
share 15.6%
|
0
share 1.0%
|
—
|
| Royalty |
1
+284.3%
share 2.7%
|
0
-1.7%
share 8.9%
|
0
+139.6%
share 2.0%
|
0
+28.2%
share 1.7%
|
0
+157.5%
share 2.6%
|
0
share 16.1%
|
0
share 2.8%
|
0
share 4.5%
|
-0
share -3.5%
|
| License And Milestone Revenue |
28
+119.7%
share 68.5%
|
0
-83.8%
share 2.5%
|
10
+666.1%
share 70.9%
|
12
+495.0%
share 83.4%
|
—
|
1
share 27.5%
|
1
share 31.9%
|
2
share 48.7%
|
—
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- OABI (Nasdaq), OABIW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Emeryville, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1846253
- Former names
- Avista Public Acquisition Corp. II (until Nov 1, 2022)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.